Antibody Libraries

Antibody Discovery

Specifica

Specifica, a Q2 Solutions Company, develops and delivers exceptional antibody libraries to support drug discovery. Our patented Generation 3 platform yields drug-like antibodies directly from selections, minimizing the need for downstream affinity and biophysical engineering.

Specifica antibody libraries deliver:

 

specifica-gen3-library-platform_v2

 

Learn about our key Antibody Discovery services:

More details about our Specifica antibody discovery campaigns and libraries at www.Specifica.bio.

Fast Discovery

Specifica provides high affinity antibodies with excellent developability and high diversity, saving time and money during development.

 

High Affinity

  • 60% of antibodies from platform have affinities below 10nM
  • 20% are in the sub-nanomolar range
  • Excluding pMHC selections, more than 75% of campaigns generate at least 1 sub-nanomolar antibody

 

High Diversity

  • AbXtract machine learning module groups antibodies into 10 to 1,000 distinct clusters
  • Provides antibodies against a wide variety of target epitopes with the potential for differential biology


Developability

  • Sequence liabilities are purged from all CDRs except HCDR3
  • More than 80% of antibodies have no measurable biophysical liabilities
  • Our antibodies behave as well as the best therapeutic antibodies

Related Thought Leaders Insights

Video

Ask the expert: Valérie Gauthier

Take a look at the in-depth processes and roles within our laboratory team, focusing on the experiences and responsibilities of Valérie Gauthier, an Associate Director. Valerie discusses her career...

Video

Ask the expert: Matthieu Daugan

Matthieu Daugan, Director of the Cell-Mediated Immunity Platform at Q² Solutions, delves into his background in immunology and virology, the intricacies of his current role, and the challenges and...

Video

Ask the expert: Azriel Lopez

Azriel Lopez, our Associate Manager of lab operations, discusses his role and journey in cell culture. He explains how his background in biotech engineering and his interest in tissue culture led him...